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More than 20% of allogeneic hematopoietic cell transplantations (HCTs) are performed in children and
adolescents at a large number of relatively small centers. Unlike adults, at least one-third of HCTs in children
are performed for rare, nonmalignant indications. Clinical trials to improve HCT outcomes in children have
been limited by small numbers and these pediatric-speciﬁc features. The need for a larger number of pediatric
HCT centers to participate in trials has led to the involvement of international collaborative groups. Repre-
sentatives of the Pediatric Blood and Marrow Transplant Consortium, European Group for Blood and Marrow
Transplantation’s Pediatric Working Group, International Berlin-Frankfurt-Munster (iBFm) Stem Cell Trans-
plantation Committee, and Children’s Oncology Group’s Hematopoietic Stem Cell Transplantation Discipline
Committee met on October 3, 2012, in Frankfurt, Germany to develop a consensus on the highest priorities in
pediatric HCT. In addition, it explored the creation of an international consortium to develop studies focused
on HCT in children and adolescents. This meeting led to the creation of an international HCT network, dubbed
the Westhafen Intercontinental Group, to develop worldwide priorities and strategies to address pediatric
HCT issues. This review outlines the priorities of need as identiﬁed by this consensus group.
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relatively more children with such diseases as acute lympho-
blastic leukemia and juvenilemyelomonocytic leukemia. There
are unique issues associated with HCT in children with
leukemia, including the fact that we are treating a developing
individual with greater susceptibility to the some of the toxic-
ities of myeloablative preparative regimens. Overall, there are
many major questions and issues unique to pediatric HCT that
need to be considered separately in clinical trials.Moreover, the
rare nature of many of the pediatric disorders treated by HCT
require a large number of transplantation centers and inter-
national trials to address some of these questions and issues.
This conclusion is well supported by the difﬁculties that have
been encountered by the Blood andMarrowTransplant Clinical
Trials Network in North America in attempting to develop
a clinical trial aimed at improving HCT for treating hemopha-
gocytic lymphophistiocytosis.
Given this clear need to develop a structure for interna-
tional trials in pediatric HCT, the 4 largest pediatric clinical
trials groups in North American and Europe met to begin the
process of developing trials to address the most compelling
questions for HCT. The groups at this meeting included the
International BFM Stem Cell Transplantation Strategy Group,
the Pediatric Blood and Marrow Transplantation Consortium
(PBMTC), the Children’s Oncology Group (COG) Hematopoi-
etic Stem Cell Transplantation Discipline Committee, and
European Group for Blood and Marrow Transplantation
(EBMT) Pediatric Working Group. The consensus group ﬁrst
met on October 3, 2013, in Frankfurt, Germany. That meeting
focused on reviewing the current status of pediatric HCT
worldwide and identifying the critical areas of need that can
be addressed only by larger multicenter studies.
HCT IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCY
Outcomes of HCT in patients with primary immune deﬁ-
ciency (PID) have improved signiﬁcantly over the last several
decades in both Europe and the United States [2]. Collabora-
tive studies evaluatingoutcomesbystemcell source aswell as
disease-speciﬁc outcomes from centers within the EBMT
Inborn ErrorsWorking Party (IEWP), the European Society for
Immunodeﬁciency (ESID), and the Center for International
Blood and Marrow Transplant Research (CIBMTR) have had
a positive impact on these outcomes [2-4]. Conclusions from
these studies include the following: (1) Patients with none
severe combined immunodeﬁciency (SCID) Tcell deﬁciencies
have poorer outcomes compared with all others; (2) patients
with SCID Bþ deﬁciencies have the best outcomes; (3) the
overall survival (OS) is similar with matched related donors
and matched unrelated donors and better with both
compared with haploidentical donors; and (4) a shorter time
from diagnosis to HCT is associated with better OS. Further-
more, in Europe, studies of reduced-toxicity regimens in
phagocytic disorders, such as chronic granulomatous disease
(CGD) and leukocyte adhesion deﬁciency, are reporting
apparent good results [4,5]. Such results may impact the
choice of conditioning regimens HCT for CGD in the United
States. In addition, antibody-based conditioning regimens,
such as monoclonal antibody targeting CD45, are now under
evaluation [6]. Collaborative studies are currentlyopenwithin
theEBMT, andanewNorthAmericanconsortium, thePrimary
Immune Deﬁciency Treatment Consortium (PIDTC), has been
created.
The major problem faced when studying children with
PID in North America is that owing to the rarity of these
disorders, as no single institution treats a sufﬁcient numberof patients to be able to implement anything other than pilot
or observational studies. Despite this limitation, over the
years centers have developed their own institutional proto-
cols and reported on their own experiences, with less
emphasis onmulti-institutional trials. The PIDTCwas formed
to overcome this deﬁciency and ro replicate the achieve-
ments of the EBMT/ESID IEWP, which has been well estab-
lished for 2 decades.
The PIDTC is a group of 33 transplantation centers in the
United States and Canada that is focused on 3 PIDs: SCID,
CGD, and Wiskott-Aldrich syndrome (WAS) [7,8]. PIDTC
retrospective, cross-sectional, and prospective studies of
SCID hope to determine the optimal conditions for HCT in
children with SCID, including donor type, donor source,
donor match, minimal conditioning regimen, and supportive
care guidelines, that result in the best long-term survival
withminimal toxicity. In addition, these studies are assessing
for unique biomarkers that can predict outcome and identify
the optimum approaches for the various SCID genotypes and
phenotypes. Finally, other research studies in long-term
survivors include quality of life, T cell tolerance mecha-
nisms, B cell reconstitution and function, and donor stem cell
chimerism. Studies of WAS and CGD are focused on the
extent of donor chimerism necessary to correct the disease
and avoid post-transplantation autoimmunity and inﬂam-
matory disease, as well as the indications for HCT. Updates on
the outcomes of these studies are presented during annual
meetings of both the IEWP and PIDTC with representative of
each group participating, but joint meetings are currently
lacking. Although a growing number of collaborations have
developed on an ad hoc basis, no formal collaborative multi-
institutional studies have been conducted to date.
New challenges and opportunities to improve the
outcomes for patients with PID are newborn screening
programs (already open in some US states) and emerging
therapies (eg, gene therapy, antibody-based conditioning).
Although SCID, WAS, and CGD are relatively more frequent
among the rare PIDs, many other serious primary disorders
of the immune system are even less common (<1/100,000
population). For many of these, even studies in Europe or
North America would enroll relatively few patients, and joint
collaborative efforts would be much more effective. More-
over, to test important therapeutic approaches, enrolling
sufﬁcient numbers of patients in a timely manner to answer
deﬁnitive questions will require collaborative efforts
between the PIDTC and IEWP. At a minimum, we need to
standardize data collection and PID deﬁnitions to compare
outcomes. Only then we can begin to work together to
develop not only collaborative retrospective analyses, but
also prospective phase III intervention trials to further
improve transplantation outcomes and, perhaps even more
importantly, long-term outcomes. After the last PIDTC
meeting in Houston, a potential PIDTC/IEWP collaborative
analysis of Immune dysregulation, polyendocrinopathy,
enteropathy, X-linked (IPEX) syndrome was proposed.
The conclusions can be summarized as follows:
1. Conducting randomized controlled trials will be difﬁ-
cult without standardization of data collection and
disease deﬁnitions.
2. Clear treatment guidelines should be developed for
patients identiﬁed in newborn screening programs. A
prospective intervention study is being planned by the
PIDTC pending funding. As European countries insti-
tute newborn screening for SCID, it is hoped that
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3. Efforts to homogenize the conditioning regimens are
supported by research data from retrospective and
prospective studies.
4. The EBMT guidelines (www.ebmt.org) may be a good
platform for the PIDTC centers. This will be discussed
within the group.
5. There is the need for a joint statement on the impor-
tance of standardized treatment guidelines for the
various disease groups. For speciﬁc diseases, special
recommendations may be needed (eg, X-linked lym-
phoproliferative disease) [9].
6. Data collection and registration are important, espe-
cially for long-termfunctional outcomes. Characterizing
the long-term outcomes and late effects in children
with, for example, SCID, WAS, or CGD who underwent
HCT is important. At present, we are using standard
registries to report these data, but a critical review is
needed to homogenize the endpoints in the EBMT
PROMISE and SCETIDE, PIDTC, and CIBMTR registries.
7. Joint meetings (once every 2 to 4 years) between EBMT
IEWP and PIDTC would be of use to further homoge-
nize HCT practice and follow-up.
OVERVIEW OF EBMT/IBFM STUDIES FOR LEUKEMIA
The major European-based cooperative groups active in
the ﬁeld of HCT for children with leukemia are the iBFM
Study Group and the EBMT’s Pediatric Disease Working
Party. Ongoing and recent European studies involving this
patient population include the following:
 CML-SCT iBFM, a study of imatinib and HCT for children
and adolescents with CML using reduced-intensity
conditioning (RIC) (ongoing, open in some European
countries only; challenged by low accrual)
 AML SCT 2007, a study of HCT in pediatric AML with
busulfan-cyclophosphamide-melphalan conditioning
for patients in complete remission with a matched
donor (ongoing)
 IntReALL, a study of frontline protocol for relapsed
acute lymphoblastic leukemia (ALL) in children
 Allogeneic Stem Cell Transplantation for Children and
Adolescents with Acute Lymphoblastic Leukaemiae
FORUM (For Omitting Radiation Under Majority age)
trial, a study of HCT in pediatric ALL.
The ALL-SCT BFM 2003 trial accrued 452 patients with
childhood ALL. The conditioning regimen was TBI/etoposide
for children age >2 years and busulfan/cyclophosphamide/
etoposide in younger patients and those with a contraindica-
tion toTBI. Graft-versus-host disease (GVHD)prophylaxiswas
cyclosporin A only for matched sibling donor (MSD) HCT and
cyclosporin A/methotrexate/antithymocyte globulin (ATG)
for matched unrelated donor (MUD) HCT. High-resolution
typing and allele matching of 9/10 or greater was required
for the MUD group. The protocol was amended to remove
peripheral blood stem cells (PBSCs) as a stem cell source,
owing to an increased risk of extensive chronic GVHD
(cGVHD) after MSD HCT. Outcomes were equivalent for
patients undergoing HCT with either an MSD or an MUD,
using either bone marrow (BM) or PBSCs as the stem cell
source, with no difference between 9/10 and 10/10 matches,
with a low 3-year TRM of 5% for MSD HCT and 10% for MUD
HCT. Poor outcomes were reported for those with MUD ormatched relateddonorswithnodifference in stemcell source,
but signiﬁcantly better OS was seen in patients at very high
risk for relapse who underwent HCT while in ﬁrst remission.
A new trial, ALL SCTped entitled FORUM, is being con-
ducted by the EBMTG pediatric working group. This trial,
a joint effort of the EBMTG, iBFM-SG, and the IntReALL known
as the “Open, Randomized, Multicenter, Controlled, Prospec-
tive Phase III Study For Therapy And Therapy Optimization in
Patients with ALL and an Indication for Allogeneic HSCT,” is
sponsored by St Anna Kinderkrebsforschung, Vienna, Austria.
Recruitment will be 1000 patients over 5 years, with 10 years
of observation. Inclusion criteria will allow any patient age
<18 years at the time of conditioning and in complete
remission. The overall goal of the study will be to show
that noneTBI-containing conditioning (ﬂudarabine/thiotepa/
bulsulfan or ﬂudarabine/thiotepa/treosulfan) will result in
noninferior survival compared with conditioning with TBI/
etoposide in children age >4 years after (HCT) using BM or
PBSCs from MSDs or MUDs. The study will also evaluate
event-free survival (EFS) after HCT in patients who receive an
HLA-mismatched transplant from a mismatched MUD, mis-
matched umbilical cord blood, or an HLA-haploidentical
family member with a noneTBI-conditioning regimen.
OVERVIEW OF COG AND PBMTC STUDIES FOR LEUKEMIA
The largest pediatric HCT cooperative groups in North
America include the COG SCT Committee [10] and the PBMTC
[11]. Whereas the COG focuses on oncology, supportive care,
and phase III trials, the PBMTC performs trials in nonmalig-
nant disorders and early-phase pilot studies that could go on
to become phase III trials in the COG. The PBMTC functions as
a core center in the National Cancer Institute/National Heart,
Lung, and Blood Instituteesponsored BMT Clinical Trials
Network (BMTCTN), and represents pediatric transplantation
interests in that forum.
The COG SCT Committee and the PBMTC have numerous
individual and joint projects. Selected studies from these
groups include the following:
 For the COG alone: ASCT1221, a comparative trial of
busulfan/ﬂudarabine versus busulfan/cyclophospha-
mide/melphalan for children with JMML
 Joint COG and PBMTC trials: ASCT0431 (recently
completed), a phase III trial comparing sirolimus con-
taining GVHD prophylaxis with standard regimens, and
ASCT0521, a phase II trial assessing the role of enta-
nercept in the treatment of idiopathic pneumonia
syndrome
 For the PBMTC alone: ONC1001, a study comparing pre-
and post-HCT minimal residual disease measurements
for patients with AML undergoing HCT; ONC1101,
a phase II study of treosulfan in children with AML/
MDS; and ONC1201, a phase II trial of moxetumomab
for reduction of minimum residual disease (MRD) in
patients with ALL before HCT
 For the COG and PBMTC with the BMT CTN: 0501,
a comparison of 1 unit and 2 unit umbilical cord blood
transplantation in children with hematologic malig-
nancies; 0601, a reduced-intensity approach to children
with sickle cell disease; and 1204, a study of optimized
timing of alemtuzumab for RIC in children with HLH
and selected immune deﬁciencies.
Another important effort of the PBMTC was an interna-
tional conference on late effects in pediatric HCT held in April
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a foundation for continued international cooperation in late
effects research [12-18].
MRD IN LEUKEMIA
The predictive value of MRD and chimerism post-HCT for
ALL has been shown to enable potential interventions to
avert a pending relapse [19-21]. Patients with rising donor
chimerism were found to have better outcomes when
a therapeutic intervention, such as withdrawal of immune
suppression and/or donor lymphocyte infusion (DLI), was
performed. MRD <104 versus 104 was used as cutoff for
ALL (based on pretreatment marrow). There was no beneﬁt
of DLI intervention at MRD >103. Chimerism used for
studies was on whole-cell populations. One emerging stan-
dard practice is analysis of MRD in BM, with proposed time
points of 30, 60, 100, 150, 200, and 300 days and 12 and
18months after HCT. Either cessation of immunosuppression
or DLI is considered at MRD 104 or if chimerism is
observed with >1% recipient.
CELLULAR AND IMMUNE THERAPIES FOR ALL
Currently, there are no leukemia-speciﬁc cellular therapy
options broadly available, so cellular therapeutic options are
limited to DLI, CIK cells, and natural killer cells. The group
proposed that studies be developed based on MRD analysis
in BM using the timing described above, plus chimerism
performed in peripheral blood at weekly intervals until day
200 and monthly thereafter. An intervention with with-
drawal of immune suppression and DLI or possibly another
immune intervention would be based on either an MRD
104 or mixed chimerism of >1%.
There is a broadly held belief that ALL is not susceptible to
the graft-versus-leukemia (GVL) effect, because DLI does not
improve outcome in ALL. The ASCT0431/ONC051NCONC051
trial, “A Randomized Trial of Sirolimus-Based GVHD Prophy-
laxis after HSCT in Selected Patients with CR1 and CR2 ALL,”
demonstrated in a prospective, multicenter, phase III
randomized trial that the GVL effect is important in prevent-
ing relapse after transplantation for pediatric ALL. Although
sirolimus has potent antileukemic activity in ALL [22-24], the
addition of this medication after transplantation did not
decrease relapse, because it also decreased acute GVHD
(aGVHD). The strongest association with decreased relapse in
this trial was noted with any occurrence of aGVHD. In addi-
tion, a very signiﬁcant risk was conferred by the presence of
MRD before or after transplantation, and this risk was greatly
increased in patients who did not experience aGVHD.
However, patients who were MRD-positive before HCT were
found to be at high risk for relapse when analyzed by the
presence or absence of aGVHD; those with aGVHD had
a relatively low risk of relapse, whereas those without aGVHD
had a 3-fold increased relapse risk. Almost all relapses
occurred by dayþ400 after HCT, but a relatively small number
occurred within the ﬁrst 50 to 200 days after HCT. This means
that there is a small window of opportunity in the immediate
post-HCT period for interventions aimed at preventing
relapse. Especially good target populations for relapse inter-
vention studies include MRD-positive patients pre-HCT who
do not develop aGVHD by day þ55 and any patient with any
level of MRD noted after HCT [25]. A ﬁrst step when giving an
agent to prevent relapse is withdrawing or decreasing
immune suppression. This by itself has been documented to
salvage a percentage of patients and will be further explored
in an upcoming COG trial. Possible agents to use ininterventions for these patients after HCT include blinatu-
momab, moxetumomab, TLR9 agonists, and leukemia-speciﬁc
chimeric antigen receptor (CAR)-armed T cells [26-29].
Blinatumomab is available in the clinical trial setting and
is now being explored in much larger studies in children
[26]. A total of 9 patients have been treated, including 1 in
ﬁrst relapse, 6 in second relapse, 1 in third relapse, and 1 in
fourth relapse [30]. Blinatumomab induces a generalized
inﬂammatory response with elevation of C-reactive protein.
This is due to cytokine release, whichmay bemediated by IL-
6 in some patients and may respond to IL-6edirected cyto-
kine blockade [31]. Treatment commonly caused weight gain
(6 of 9 patients) and AST/ALT elevation (9 of 9). Mild central
nervous system toxicities (3 of 9; ataxia, tremor), and
peripheral neuropathy has been observed. Major toxicities,
such as seizures, were relatively infrequent (1 of 9).
Management of toxicities include antipyretics (eg, meta-
mizole, paracetamole), ﬂuid support and pressors as needed
for hypotension, and dexamethasone prophylaxis and
treatment in the event of developing cytokine release
syndrome. Of the 9 patients treated under compassionate
use, 6 achieved complete remission. The long-term outcome
with blinatumomab is unclear, but that it is effective for
remission induction. It is probably effective in patients with
frank relapse, but may have the highest efﬁcacy in MRD-
positive patients.
Another approach to controlling disease in ALL involves
the use of CAR-armed T cells. In B cell malignancies, such as
CLL [32,33] and now pediatric ALL [29], these genetically
engineered T cells have shown signﬁcant activity against
relapsed/refractory disease. In addition, some early cases
treated with CAR T cells have shown long persistence and
disease control for up to 2.5 years. Studies with engineered
T cells are being pursued in several instutions, with multi-
institutional trials now in the planning stages. The role of
CAR T cells in ALL and lymphoma will be further clariﬁed in
these trials, particularly in terms of whether cell therapy can
act as a bridge to allogeneic HCT, or perhaps even a replace-
ment for it.
WHICH ALL GROUPS SHOULD BE UNDERGO HCT?
There is a paucity of randomized clinical trials that have
rigorously evaluated HCT versus intensive chemotherapy for
ALL; however, some common practice patterns have
emerged over the past few years. In de novo ALL, patients
with high-risk cytogenetic abnormalities, including BCR/ABL,
hypodiploid ALL, and MLL rearrangements are considered
candidates for HCT in ﬁrst clinical remission (CR1). However,
with the recent results from the COG using TKIs versus HSCT
in patients with Philadelphia chromosomeepositive (Phþ)
ALL provide interesting insights into the role of HCT in this
disease [34]. Updates from COG study AALL0031 revealed no
signiﬁcant differences (P ¼ .93) in the estimates of EFS for
patients with Phþ ALL enrolled on cohort 5 receiving imati-
nib (EFS, 84%  7%) versus patients who underwent MSD
HCT (EFS, 77%  12%) versus those who received a MUD HCT
(EFS, 83%  15%) [35]. This was not a randomized compar-
ison, and an additional caveat is that the cohort who received
HCT was small. More recently, a joint European/COG study
(AALL1122/BMS CA180-372) is currently assessing outcomes
in patients with Phþ ALL treated with dasatinib and the
EsPhALL chemotherapy backbone; however, a slow response
to induction and/or consolidation therapy are criteria for
proceeding to allogeneic HCT in that study. Although the
foregoing studies may call into question the role of HCT as
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socioeconomic factors also also contribute to this decision
making process, especially when considering concerns about
compliance over years of therapy and the cost of prolonged
TKI therapy versus the proven long-term success of HSCT as
a curative treatment strategy for patients with Phþ ALL.
Similarly, other small molecules are currently being
developed for other gene targets in ALL. Recently, cytogenetic
abnormalities that involve genes signaling in the Ras/MAPK
pathway have been identiﬁed in hypodiploid ALL and may be
targets for novel therapies [36]. The discovery of mutations
activating the Janus kinase (JAK) pathway in patients with
high-risk ALL have raised the possibility that JAK inhibitors
such as ruxolitinib may be useful in this subset of patients
[37,38]. Importantly, a high rate of TP53 mutations has been
identiﬁed in patients with low hypodiploid ALL (32 to 39
chromosomes). Approximately 45% of these patients were
subsequently found to have germline events, thus ﬁrmly
establishing this subtype of childhood ALL within the Li-
Fraumeni syndrome. Thus, the discovery of germline TP53
mutations supports referral for assessment of genetic risk, to
allow initiation of early monitoring for other cancers in the
patient and family members. Nevertheless, until the safety
and efﬁcacy of novel targeted therapies are evaluated in vivo,
it will remain common practice to proceed to allogeneic HCT
in CR1 for these high-risk patients.
Older patients with MLL rearrangements have been re-
ported to do less well with current conventional therapies.
Thus, the general recommendation is to refer these patients
for HCT while in CR1. However, recent data presented at the
2012 SIOP meeting suggest that patients with MLL rear-
rangements who respond rapidly to induction therapy may
achieve durable responses with intensive BFM-style therapy.
In particular, for the NCI-HR group, patients with MLL rear-
rangements without evidence of residual BM disease at day
29 using ﬂow cytometric methods (MRD <0.1%) had a 5-year
EFS of 77.7% (SE 0.07).
Finally, slow response to induction therapy has been the
single most important risk factor for relapse [39]. Many
centers pursue HSCT early for patients with frank induction
failure (day 29 BM with >25% lymphoblasts) after reinduc-
tion strategies. A recent report from the Ponte di Legno group
published outcomes for patients with induction failure [40].
Out of a total of 44,017 patients, 1041 patients failed induc-
tion (2.4%). Of the 198 patients who underwent HCT, trans-
plantation was beneﬁcial for those with T cell ALL (n ¼ 71)
who were considered induction failures. However, this study
suggested that HCT might not be beneﬁcial for children with
B-lineage ALL age<6 years at diagnosis and who do not have
an MLL gene rearrangement, although the number of these
children was relatively small (n ¼ 32). Furthermore, the
beneﬁt of HSCT could not be conﬁrmed in patients with MLL
rearrangements, owing to the small number of patient. In
summary, indications for HCT in CR1 appear to be evolving as
upfront therapy intensiﬁes or incorporatesmolecular targets.
However, for many high-risk patients, HCT currently remains
the only readily available and potentially curative treatment
option. Thus, novel approaches focused on conditioning
regimens, graft sources, and post-HSCT supportive care
strategies should be considered as priorities for development
to improve outcomes in high-risk patients with ALL.
HCT FOR HEMOGLOBINOPATHIES
The probability of survival with HLA-matched sibling
transplants reported by the Pesaro group in more than 900patients with thalassemia age <35 years is 73% [41]. Risk
factors validated in pediatric patients and predictive of poor
outcomes include irregular chelation, presence of hepato-
megaly, and hepatic ﬁbrosis. Considering these risk factors,
3 classes of risk have been identiﬁed with different
outcomes: class I, in which none of these 3 risk factors is
present, associated with disease-free survival (DFS) of 87%
and treatment-related mortality (TRM) of 8%; class II,
including children with 1 or 2 risk factors, associated with
DFS of 84% and TRM of 14%; and class III, including children
with all 3 risk factors, associated with DFS of 65% and TRM of
25% [41]. Outcomes of adults with thalassemia major
undergoing HCT with a graft from an HLA-identical sibling
are comparable to those of class III pediatric patients. The
majority of TRM is toxicity-related (organ damage).
Bernardo et al. [42] recently reported results obtained
using a treosulfan-based regimen for thalassemia. Their
regimen, consisting of thiotepa, treosulfan, and ﬂudarabine
followed by 9-10/10 HLA-matched allogeneic HCT from
either a related or an unrelated donor resulted in survival in
the 80% range for all risk classes. Outcomes were comparable
in related and unrelated donor HCT recipients. In view of
these results, this preparative regimen merits further
investigation. A French study of sickle cell disease evaluated
patients who underwent HLA-identical sibling HCT or cord
blood transplantation after a busulfan/cyclophosphamide
preparative regimen [43]. The update of the original analysis
was presented; a large proportion of patients also received
rabbit ATG. The combination of cyclosporine and short-term
methotrexate was used for GVHD prophylaxis. The 5-year OS
was 95%. The addition of ATG signiﬁcantly reduced the
rejection rate, from 35% to 2%.
There is a high potential for international interaction for
transplantation studies in hemoglobinopathies. In this
regard, it is noteworthy that the Eurocord and EBMT have
performed a joint retrospective study comparing the use of
cord blood with HCT in patients with hemoglobinopathies.
The CIBMTR has examined similar analyses in North Amer-
ica. In Europe, France, the United Kingdom, and Monte Carlo
were funded for an International Observatory on Sickle Cell
Disease grant from Monaco to establish a group of experts
(leader, Eliane Gluckman). A recent evaluation of HCT per-
formed in adults with sickle cell disease (SCD) in Europe
based on the EBMT registry identiﬁed 35 adults with SCD
who had undergone HCT, 10 of whom received an RIC
regimen and 25 of whom received myeloablative con-
ditioning, and found an OS of 81%. Opportunities for inter-
national studies in hemaglobinopathies include quality of
life studies; comparative effectiveness research (HCT versus
no HCT); randomized clinical trials evaluating treosulfan-
based versus busulfan-based regimens; introduction of
ATG to the conditioning regimen, tested in a randomized
fashion; long-term outcomes for SCD/thalassemia; strate-
gies to enhance survival of alternative donor recipients, such
as mismatched donors, cord, and haploidentical donors; and
evaluation of stable donor chimerism in patients with SCD/
thalassemia [44,45].
HCT for treating hemoglobinopathies in North America
has pursued similar strategies. MSD, umbilical cord blood,
and BM transplantation after primarily busulfan-based
myeloablative regimens have shown good outcomes.
Reports from multicenter trials and the CIBMTR registry
have shown good efﬁcacy, with DFS of 79% to 90% in Pesaro
low-risk and 62% in high-risk class III thalassemia [46,47].
The small number of actual transplantations despite no lack
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MSD, organ toxicities (eg, hepatic sinusoidal obstruction
syndrome, seizures, gonadal failure, growth inhibition in
adolescent recipients), and worse outcomes/toxicities in
vulnerable subgroups (eg, older patients, advanced disease,
unrelated donors) [48-50]. Transplant trials focusing on
these obstacles are moving forward. Although graft rejec-
tion is a risk owing to immune competency, nonablative
immunosuppression (eg, alemtuzumab, low-dose TBI)
before receipt of a mobilized PBSC graft from an MSD was
found to support long-term mixed chimerism in 74% of
adults with SCDwhen sirolimus was continued for tolerance
induction. Successful engraftment (6 of 7) has been reported
with MSD marrow after an RIC regimen of busulfan, ﬂu-
darabine, ATG, and total lymphoid radiation [51,52]. RIC
(with ATG, ﬂudarabine, cyclophosphamide, and 2 Gy TBI)
HLA-haploidentical HCT with cyclophosphamide-based
GVHD prophylaxis resulted in engraftment in 57% of SCD
recipients, including adults [53]. Based on successful RIC
HCT with alemtuzumab, ﬂudarabine, and melphalan in
nonmalignant disorders (NCT00920972), a national unre-
lated trial is currently in progress for children with severe
SCD (0601; the sickle cell unrelated donor transplant
[SCURT] trial) but is restricted to BM because of graft
rejection with cord blood as the stem cell source [54,55].
This trial is a cooperative effort of the National Marrow
Donor Program, BMT CTN, Sickle Cell Disease Clinical
Research Network, and PBMTC. Subsequently, a similar RIC
trial (supported by the Thalassemia Clinical Research
Network and PBMTC) for thalassemia-included hydroxyurea
and thiotepa has completed enrollment with unrelated BM
and cord (the URTH trial). RIC HCT aims to achieve stable full
or mixed donor chimerism and is under evaluation for safety
and success.
Cautious expansion of donor sources with formal proto-
cols that explore reduced intensity and/or toxicity are justi-
ﬁed in hemoglobinopathy. As the North American studies are
concluded, there is a general consensus that international
trials for both thalassemia and in particular SCD should be
considered using a RIC approach with alternative donors.
Areas of promise for cooperative international efforts include
the following:
1. Comparing long-term outcomes and quality of life
among various transplantation approaches to continue
to improve on existing results
2. Deﬁning acceptable levels of mixed chimerism with
longitudinal follow-up studies
3. Deﬁning the population of patients (particularly those
with SCD) best served by early transplantation plan-
ning based on outcome analyses.
HCT IN METABOLIC DISEASES
During 3 decades of HCT for inborn errors of metabolism
(IEM), important lessons have been learned about trans-
plantation- and disease-speciﬁc factors that affect engrafted
survival and long-term outcomes. Children with MPS IH
(Hurler’s disease) have beneﬁted from many advances,
including the development of worldwide guidelines for
evaluation and treatment [56,57]. The importance of early
diagnosis and prompt HCT, using cord blood as the cell
source, for patients with excellent performance scores is
clear [58]; outcomes are worse in symptomatic patients
(usually associated with poor performance scores) [59].
Efforts aimed at early diagnosis and treatment have hadfavorable affects in all children with IEM. This should be the
focus in the future as well. Developments in newborn
screening and therapy will facilitate early diagnosis and
direct greater attention to genotype/phenotype correlation.
The rare nature of these disorders necessitates a world-
wide network for a collaborative international, multicenter,
and interdisciplinary research approach. This is of utmost
importance given the development of new treatment
modalities, including gene therapy and combined HCT and
enzyme replacement therapy. Especially for these rare
diseases, data collection and registration need to be homog-
enized between the EBMTand CIBMTR registries, to facilitate
comparison of outcomes and reasonable discussions.
Furthermore, collaborative longitudinal studies can provide
a better understanding not only of survival, but also of func-
tional abilityandqualityof life afterHCT forpatientswith IEM.
The conclusions can be summarized as follows:
1. The rare nature of these disorders necessitates
a worldwide network for collaborative international,
multicenter, and interdisciplinary research.
2. Clear treatment guidelines should be developed for
patients identiﬁed in newborn screening programs.
3. Efforts should be undertaken to homogenize data
collection, especially regarding long-term functional
outcomes. Currently, standard registries are used for
reporting data, but a critical review is needed to
homogenize the endpoints in the EBMT and CIBMTR
registries.
4. Joint meetings (once every 2 or 4 years) of the EBMT
IEWP and Working Committee of the CIBMTR will be
important to further homogenization of HCT practices
and follow-up.
CHALLENGES FOR INTERNATIONAL GVHD STUDIES
GVHD remains a leading cause of morbidity andmortality
for children who undergo allogeneic HCT, with the ongoing
critical need for more effective preventive and treatment
strategies. Although clinical characteristics, such as donor
type and donorerecipient HLA mismatch, predict an
elevated risk of GVHD, there are currently no diagnostic tests
that can reliably predict occurrence, severity, or response to
therapy. Recent compelling results from single-center
studies suggest that biomarkers (protein, DNA, RNA, and
cellular) can be identiﬁed to stratify patients into discrete
risk groups for outcomes and overall mortality; however,
these relatively small studies generally lack the necessary
statistical power or validation to allow the incorporation of
their results into practice. A future focus of GVHD research
will be on developing biomarker-based strategies that allow
for individualized treatment assignments based on the
likelihood of GVHD or response to therapy [60].
One key factor in the success of biomarker studies is the
quality of clinical outcomes data linked to the specimens
being analyzed. Most international clinical registries include
mostly GVHD data limited to the presence of aGVHD and
cGVHD and maximum grade of aGVHD. Information such as
date of onset, date of response or resolution, and manage-
ment strategies is scarce or absent in these registries.
Moreover, existing GVHD staging and grading deﬁnitions
often lack clarity and reproducibility. For example, a patient
with gastrointestinal GVHD experiencing occasionally
bloody, low-volume diarrhea may be categorized as GVHD
stage 0 (absent) or stage 4 (life-threatening) on different days
in the same week with no signiﬁcant change in treatment or
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GVHD, infection, or multiorgan system failure, leading to
misunderstanding of the speciﬁc barriers to success in
various scenarios. Another major barrier is that data at the
onset of symptoms and after initiation of treatment lack
sufﬁcient detail and consistency to enable comparison of
results among different centers. All of these data-related
problems impair the integration of laboratory values into
overall schema that can predict clinical outcomes.
To maximize the beneﬁt of potential GVHD biomarkers, it
will be necessary to standardize data collection strategies
internationally to make granular GVHD data available.
Furthermore, expert consensus panels need to adjudicate
“gray areas" to develop consistent deﬁnitions for the
complex clinical scenarios not envisioned when the current
GVHD staging and grading system was initially proposed
nearly 20 years ago [61]. It is anticipated that these expert
panels will function best when the data are reviewed in near
real time, when memories are fresh and feedback to centers
supplying the data can be given. Although effort-intensive,
a strategy of this nature will speed the adoption of harmo-
nized data strategies across themany centers worldwide that
perform pediatric allogeneic HCT.
EBMTG/IBFM GVHD TRIALS (IN STEROID-REFRACTORY
GVHD)
In addition to causing direct target organ toxicity, GVHD
and its treatments are associated with infections and long-
term side effects. In children with hematologic malignan-
cies, GVHD may be beneﬁcial to some extent because of its
associated (albeit limited) GVL effect. However, the immu-
nosuppressive treatment required to control GVHD may
interfere with or preclude potential post-transplantation
immunotherapeutic interventions. Prevention and rapid
recognition and control are important goals in the manage-
ment of GVHD. Systemic treatment with high-dose steroids
is very effective and remains the ﬁrst-choice treatment;
however, approximately half of patients experience steroid
refractoriness or dependency. Evidence of the efﬁcacy of
second-line treatment modalities is limited, and studies are
often hampered by small numbers of patients and single-arm
study designs [62].
Along with immunosuppressive and modulatory drugs,
the potential of 2 novel therapies, extracorporeal photo-
pheresis (ECP) and in vitro expanded mesenchymal stromal
cells (MSCs), has been reported in some recent studies.
Clinical outcomes with ECP in children with aGVHD have
been evaluated in 7 single-arm studies with a total of 155
patients. The response rate (CR/partial response [PR]) was
74%, with steroid reduction in responding patients. OS was
57%, and was signiﬁcantly higher in ECP responders
compared with nonresponders [63]. Predictive clinical/bio-
logical markers for response to treatment have not yet been
identiﬁed.
Following the initial study reported by le Blanc et al. [64]
on behalf of the EBMT Developmental Committee, clinical
experience with MSC treatment in children with steroid-
refractory GVHD has been evaluated in several single-arm
studies with a total of 61 patients. Three additional studies
are now closed, with reports expected soon. The response
rate (CR/PR) in the published studies is 82% [65]. So far, there
is no evidence of increased rates of relapse or infection,
ectopic tissue formation, or MSC transformation. Similar to
the experience with ECP, there is currently a lack of data on
reliable predictive clinical/biological parameters for MSC-treated patients. Overall, both ECP and MSC treatment
appear to be feasible and safe therapeutic modalities in
children, with promising efﬁcacy in steroid-resistant aGVHD.
Several registered ECP and MSC therapeutic trials are
currently recruiting, including a randomized ECP trial.
Randomized trials of MSC treatment of steroid-refractory
GVHD in both children and adults are underway.
Randomized controlled trials, preferably multicenter and
multinational, to evaluate the therapeutic efﬁcacy of ECP,
MSC, and pharmacologic agents as second-line treatment
modalities in steroid-refractory GVHD are clearly needed.
Biological monitoring is pivotal in these studies and should
involve evaluation of both soluble and cellular biomarkers, as
well as histological analysis of GVHD-affected tissues [66].
CHRONIC GVHD BIOMARKER TRIALS
Various adult studies have demonstrated a predominance
of B cell activation markers and autoantibody production as
markers for cGVHD [67-69]. Pediatric cGVHD biomarkers
were ﬁrst studied on a multicenter basis in the COG
ASCT0031 trial. That study reported 6 biomarkers that were
identiﬁed in the smaller multicenter study, including the
cellular markers CpG ODN-responding/TLR9-expressing B
cells (with cGVHD) and INF-g CD4þ Tcells (tolerance), as well
as plasma biomarkers, including sBAFF, anti-dsDNA antibody,
sIL-2Ra, and sCD13 [70,71]. A combination of these 4 plasma-
based biomarkers resulted in an overall diagnostic sensitivity
of 84% when 1 or more of the 4 markers were positive and
56% when 2 or more of the 4 markers were positive. The
speciﬁcity was 100% when 1 or no biomarkers was positive,
and the positive predictive value was 100% when 2 or more
of the 4 biomarkers were positive. Future studies are needed
to validate biomarkers for their ability to diagnose cGVHD; to
evaluate the ability of biomarkers to predict therapeutic
response, allowing for development of a risk and therapy
assignment strategy; and to evaluate the ability of bio-
markers to predict later onset of cGVHD. Current studies in
Canada of 250 adults are aiming to validate the pediatric-
based biomarkers in adults with patients from the CBMTG
0601 and 0801 clinical trials and from Stephanie Lee’s U01-
funded trial. These studies are evaluating these biomarkers
for their ability to diagnose cGVHD and to predict therapeutic
response, with the goal of developomg risk and therapy
assignment strategies. Discovery-based assays (proteomics
and microarrays) are being performed to identify new
biomarkers that can be used to diagnose or classify the risk of
cGVHD. A new pediatric cGVHD biomarker study, Applied
Biomarkers in Long-Term Effects of Children and Adolescents
treated for Cancer (ABLE), is being opened in Canada by the
PBMTC. This study will enroll 300 pediatric allo-HSCT
recipients prospectively over the next 3 years.
The conclusions can be summarized as follows:
1. There was general consensus that standardized
approaches for the collection of samples and the type of
clinical data collected need to be standardized to allow
for future studies and sharing among biorepositories.
2. A working group should be formed to further develop
these approaches. There will be a expert consensus
meeting aimed at promulgating standards in pediatric
ECP on behalf of the EBMT’s Pediatric Disease Working
Party.
3. To enhance pediatric data, a questionnaire on centers’
strategy for pediatric ECP will be circulated upfront,
and some US centers will join in.
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The Westhafen Intercontinental Group has concluded
that international studies are essential to further the practice
of pediatric HCT owing to the complexity, diversity, and
rarity of pediatric disorders treated by HCT worldwide. An
initial step of merging the activities of the largest cooperative
groups, including the PBMTC, EBMTG Pediatric Working
Group, iBFM SCT Group, and the COG HSCT Strategy Group, is
critical. Such a consortium will allow for database-driven
studies using the EBMT and CIBMTR registries, as well as
the implementation of international trials focused on rare
diseases that can be addressed only by larger international
consortia. This international pediatric HCT group formed at
the meeting in Frankfurt chose a name, the Westhafen
Intercontinental Group, reﬂective of that city and the
importance of multinational collaboration.ACKNOWLEDGMENTS
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